J&J says Tremfya posts sustained Crohn’s remission through 3 years in Phase 3 GALAXI studies

Johnson & Johnson disclosed new three-year Phase 3 data for Tremfya in moderate to severe Crohn’s disease. Results were set for presentation at the American College of Gastroenterology 2026 annual meeting. Patients maintained symptom control and intestinal healing through three years across both maintenance dosing regimens. Safety through three years matched Tremfya’s established profile in Crohn’s disease, supporting long-term use in a chronic indication. Data strengthen the commercial case for Tremfya as a long-duration inflammatory bowel disease therapy, alongside its ulcerative colitis franchise. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein. (C)